Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: Preliminary results of a multicentre phase II trial

Bolla, M.; Hannoun-Lévi, J.-M.; Ferrero, Jean-­Marc; Maingon, P.; Buffet-Miny, J.; Bougnoux, A.; Bauer, Jacques; Descotes, Jean‐Luc; Fourneret, Philippe; Jover, Florence; Colonna, Marc

doi:10.1016/j.radonc.2010.08.012

Cited by 32 publications

(28 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 Several trials have evaluated tolerance to DTX combined with hormonal therapy and RT for high-risk PCa. 2,18,19 The results of a Phase II trial showed that although feasible, 30% of Grade 3 or higher toxicities was observed. 2 More recently, the GETUG-12 trial found improved relapsefree survival with sequential DTX combined with HT and RT compared with HT alone.…”

Section: Discussionmentioning

confidence: 99%

“…2,18,19 The results of a Phase II trial showed that although feasible, 30% of Grade 3 or higher toxicities was observed. 2 More recently, the GETUG-12 trial found improved relapsefree survival with sequential DTX combined with HT and RT compared with HT alone. 18 As a consequence, it seems interesting to develop chemoradiation treatments in high-risk PCa, as they may improve the therapeutic ratio by decreasing systemic toxicities while maintaining a high radiosensitizing effect when delivered concomitantly.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model

Mirjolet¹,

Boudon²,

Loiseau³

et al. 2017

IJN

View full text Add to dashboard Cite

IF 4.320International audienceAround 40% of high-risk prostate cancer patients who undergo radiotherapy (RT) will experience biochemical failure. Chemotherapy, such as docetaxel (DTX), can enhance the efficacy of RT. Multidrug resistance mechanisms often limit drug efficacy by decreasing intracellular concentrations of drugs in tumor cells. It is, therefore, of interest to develop nanocarriers of DTX to maintain the drug inside cancer cells and thus improve treatment efficacy. The purpose of this study was to investigate the use of titanate nanotubes (TiONts) to develop a TiONts-DTX nanocarrier and to evaluate its radiosensitizing in vivo efficacy in a prostate cancer model. In vitro cytotoxic activity of TiONts-DTX was evaluated using an MTS assay. The biodistribution of TiONts-DTX was analyzed in vivo by single-photon emission computed tomography. The benefit of TiONts-DTX associated with RT was evaluated in vivo. Eight groups with seven mice in each were used to evaluate the efficacy of the nanohybrid combined with RT: control with buffer IT injection ± RT, free DXL ± RT, TiONts ± RT and TiONts-DXL ± RT. Mouse behavior, health status and tumor volume were monitored twice a week until the tumor volume reached a maximum of 2,000 mm3. More than 70% of nanohybrids were localized inside the tumor 96 h after administration. Tumor growth was significantly slowed by TiONts-DTX associated with RT, compared with free DTX in the same conditions (P=0.013). These results suggest that TiONts-DTX improved RT efficacy and might enhance local control in high-risk localized prostate cancer

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model

Mirjolet¹,

Boudon²,

Loiseau³

et al. 2017

IJN

View full text Add to dashboard Cite

show abstract

“…(11) Combined chemo-radiation therapy (CRT) requires synchronization of the two modalities to achieve maximum benefit. (32–33) Several drugs are being currently tested as a radiosensitizer with external beam radiation therapy (EBRT) in a large ongoing multinational randomized trial. (34) However systemic administration of these drugs have several drawbacks like high systemic toxicity, fast pharmacokinetics, limited periods of radiosensitization that are not synchronized with the radiation dosage and poor spatial distribution in tumor.…”

Section: Discussionmentioning

confidence: 99%

Nanoparticle-Based Brachytherapy Spacers for Delivery of Localized Combined Chemoradiation Therapy

Kumar

Belz

Markovic

et al. 2015

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose In radiation therapy (RT), brachytherapy inert source spacers are commonly used in clinical practice to achieve high spatial accuracy. These implanted devices are critical technical components of precise radiation delivery but provide no direct therapeutic benefits. Materials and Methods Here we have fabricated Implantable Nanoplatforms or Chemo-Radiation Therapy (INCeRT) spacers loaded with silica nanoparticles (SNPs) conjugated containing a drug, to act as a slow release drug depot for simultaneous localized chemo-radiation therapy. The spacers are made of poly(lactic-coglycolic) acid (PLGA) as matrix, were physically identical (size) to the commercially available brachytherapy spacers (5mm×0.8mm). The silica nanoparticles with diameter 250nm conjugated with near infrared fluorophore Cy7.5 as a model drug and the INCeRT spacers were characterized in terms of size, morphology and composition using different instrumentation techniques. The spacers were further doped with anticancer drug, docetaxel. We have evaluated the in vivo stability, biocompatibility and biodegradation of these spacers in live mouse tissues. Results The electron microscopy studies showed that nanoparticles were distributed throughout the spacers. These INCeRT spacers remained stable and can be tracked using optical fluorescence. In vivo optical imaging studies showed a slow diffusion of nanoparticles from the spacer to the adjacent tissue as opposed to the control Cy7.5-PLGA spacer which showed rapid disintegration in a few days with a burst release of Cy7.5. The docetaxel spacers showed suppression of tumor growth as opposed to control mice over 16 days. Conclusions The imaging with the Cy7.5-spacer and therapeutic efficacy with docetaxel-spacers supports the hypothesis that INCeRT spacers can be used for delivering the drugs in slow, sustained manner in conjunction with brachytherapy, as opposed to rapid clearance of the drugs when administered systemically. The results demonstrate that these spacers with tailored release profiles have potential in improving the combined therapeutic efficacy of chemo-radiation therapy (CRT).

show abstract

“…Prior Phase I trials have reported 20 mg/m 2 weekly docetaxel as the dose-limiting toxicity combined with 3D conformal radiation therapy [27]. Bolla et al reported a Phase II trial with 3D-CRT and 20 mg/m 2 docetaxel, reporting a moderate/high grade of toxicity, with 74% presenting enteritis [28]. However, a recently published Phase I trial has shown that weekly docetaxel at 20 mg/m 2 is safe with IMRT at doses of 78 Gy, with a biochemical progression-free survival of 94% at 2 years [29].…”

Section: Integration Of Chemotherapy With Adt and Radiotherapymentioning

confidence: 99%

Advances in the treatment of prostate cancer with radiotherapy

Gómez-Millán

Lara

Generoso

et al. 2015

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: Preliminary results of a multicentre phase II trial

Cited by 32 publications

References 28 publications

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model

Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model

Nanoparticle-Based Brachytherapy Spacers for Delivery of Localized Combined Chemoradiation Therapy

Advances in the treatment of prostate cancer with radiotherapy

Contact Info

Product

Resources

About